Literature DB >> 17454882

Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer.

Astrid T Stormorken1, Neal Clark, Eli Grindedal, Lovise Maehle, Pål Møller.   

Abstract

OBJECTIVE: In recent years persons at risk for colorectal cancers (CRC) have been subjected to follow-up with colonoscopy in many centres. There is, however, limited knowledge about the effect of such interventions. The objective of this study was to report the results of our observations during the past 15 years.
MATERIAL AND METHODS: Healthy persons were included in the study according to their family history of CRCs, and prospectively followed with colonoscopies.
RESULTS: Altogether, 1133 individuals were included and observed for a total of 3474 follow-up years from the first to the last colonoscopy initiated by our activity. Mismatch repair (MMR) mutations were detected in 6.5% of cases. A total of 1383 polyps were removed, 72% were less than 5 mm in diameter. Findings were scored as hyperplastic polyps (n=887), adenomas with mild to moderate dysplasia (n=460), adenomas with high-grade dysplasia (n=30) and cancers (n=6). Two cancers were observed after the first colonoscopy, compared with 2.6 expected by chance and more than 20 expected under the hypothesis of predominant inherited diseases in the families. Observed annual incidence rates for adenomas were similar in all groups, while in the mutation carriers there was a higher frequency of progression to severe dysplasia or infiltrating cancer.
CONCLUSIONS: A simple explanation for the combined findings may be that all selected families had a similar tendency to produce adenomas, while mutation carriers more frequently demonstrated dysplasia/cancer in the adenomas. The low annual incidence rates for CRC indicated that the removal of adenomas may have prevented cancers.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17454882     DOI: 10.1080/00365520601010230

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  10 in total

1.  Current Lynch syndrome tumor screening practices: a survey of genetic counselors.

Authors:  Stephanie A Cohen
Journal:  J Genet Couns       Date:  2013-05-15       Impact factor: 2.537

Review 2.  Liquid Biopsy as a Source of Nucleic Acid Biomarkers in the Diagnosis and Management of Lynch Syndrome.

Authors:  Gergely Buglyó; Jakub Styk; Ondrej Pös; Ádám Csók; Vanda Repiska; Beáta Soltész; Tomas Szemes; Bálint Nagy
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208

3.  Translational research in cancer genetics: the road less traveled.

Authors:  S D Schully; C B Benedicto; E M Gillanders; S S Wang; M J Khoury
Journal:  Public Health Genomics       Date:  2009-12-29       Impact factor: 2.000

4.  High risk of endometrial cancer in colorectal cancer kindred is pathognomonic for MMR-mutation carriers.

Authors:  Eli Marie Grindedal; Ignacio Blanco; Astrid Stormorken; Lovise Maehle; Neal Clark; Sara González; Gabriel Capella; Hans Vasen; John Burn; Pål Møller
Journal:  Fam Cancer       Date:  2008-10-08       Impact factor: 2.375

Review 5.  Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).

Authors:  H F A Vasen; G Möslein; A Alonso; I Bernstein; L Bertario; I Blanco; J Burn; G Capella; C Engel; I Frayling; W Friedl; F J Hes; S Hodgson; J-P Mecklin; P Møller; F Nagengast; Y Parc; L Renkonen-Sinisalo; J R Sampson; A Stormorken; J Wijnen
Journal:  J Med Genet       Date:  2007-02-27       Impact factor: 6.318

6.  Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.

Authors:  Pål Møller; Toni Seppälä; Inge Bernstein; Elke Holinski-Feder; Paola Sala; D Gareth Evans; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf Sijmons; Jacqueline Jeffries; Hans Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul Wijnen; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Laura Renkonen-Sinisalo; Ian M Frayling; John-Paul Plazzer; Kirsi Pylvanainen; Julian R Sampson; Gabriel Capella; Jukka-Pekka Mecklin; Gabriela Möslein
Journal:  Gut       Date:  2015-12-09       Impact factor: 23.059

7.  Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report.

Authors:  Toni Seppälä; Kirsi Pylvänäinen; Dafydd Gareth Evans; Heikki Järvinen; Laura Renkonen-Sinisalo; Inge Bernstein; Elke Holinski-Feder; Paola Sala; Annika Lindblom; Finlay Macrae; Ignacio Blanco; Rolf Sijmons; Jacqueline Jeffries; Hans Vasen; John Burn; Sigve Nakken; Eivind Hovig; Einar Andreas Rødland; Kukatharmini Tharmaratnam; Wouter H de Vos Tot Nederveen Cappel; James Hill; Juul Wijnen; Mark Jenkins; Maurizio Genuardi; Kate Green; Fiona Lalloo; Lone Sunde; Miriam Mints; Lucio Bertario; Marta Pineda; Matilde Navarro; Monika Morak; Ian M Frayling; John-Paul Plazzer; Julian R Sampson; Gabriel Capella; Gabriela Möslein; Jukka-Pekka Mecklin; Pål Møller
Journal:  Hered Cancer Clin Pract       Date:  2017-10-10       Impact factor: 2.857

Review 8.  Recent advances in Lynch syndrome.

Authors:  Xi Li; Guodong Liu; Wei Wu
Journal:  Exp Hematol Oncol       Date:  2021-06-12

9.  Lack of association between screening interval and cancer stage in Lynch syndrome may be accounted for by over-diagnosis; a prospective Lynch syndrome database report.

Authors:  Toni T Seppälä; Aysel Ahadova; Mev Dominguez-Valentin; Finlay Macrae; D Gareth Evans; Christina Therkildsen; Julian Sampson; Rodney Scott; John Burn; Gabriela Möslein; Inge Bernstein; Elke Holinski-Feder; Kirsi Pylvänäinen; Laura Renkonen-Sinisalo; Anna Lepistö; Charlotte Kvist Lautrup; Annika Lindblom; John-Paul Plazzer; Ingrid Winship; Douglas Tjandra; Lior H Katz; Stefan Aretz; Robert Hüneburg; Stefanie Holzapfel; Karl Heinimann; Adriana Della Valle; Florencia Neffa; Nathan Gluck; Wouter H de Vos Tot Nederveen Cappel; Hans Vasen; Monika Morak; Verena Steinke-Lange; Christoph Engel; Nils Rahner; Wolff Schmiegel; Deepak Vangala; Huw Thomas; Kate Green; Fiona Lalloo; Emma J Crosbie; James Hill; Gabriel Capella; Marta Pineda; Matilde Navarro; Ignacio Blanco; Sanne Ten Broeke; Maartje Nielsen; Ken Ljungmann; Sigve Nakken; Noralane Lindor; Ian Frayling; Eivind Hovig; Lone Sunde; Matthias Kloor; Jukka-Pekka Mecklin; Mette Kalager; Pål Møller
Journal:  Hered Cancer Clin Pract       Date:  2019-02-28       Impact factor: 2.857

Review 10.  The Prospective Lynch Syndrome Database reports enable evidence-based personal precision health care.

Authors:  Pål Møller
Journal:  Hered Cancer Clin Pract       Date:  2020-03-14       Impact factor: 2.857

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.